News from shionogi inc

Jul 03, 2014, 09:00 ET

It's Time to Talk about Sex After Menopause, A New Campaign To Free Women From The Silence Around An Often-Neglected Area Of Women's Health

 Beginning July 4th, women, men and health care providers are encouraged to lend their social voices to an often-neglected area of women's...

Jan 13, 2014, 09:00 ET

Shionogi Inc. Announces Co-Promotion Agreement with Noven Pharmaceuticals For Brisdelle™ (Paroxetine) Capsules

 Shionogi Inc. today announced that it has entered into an exclusive, multi-year agreement with Noven Pharmaceuticals to co-promote...

Jun 25, 2013, 06:30 ET

Actress Virginia Madsen Partners With Shionogi Inc. To Empower Postmenopausal Women To Break The Silence Around Painful Intercourse Due To Menopause

Academy Award-nominated actress Virginia Madsen is never one to shy away from a conversation, even if the topic at first blush seems awkward or...

May 16, 2013, 11:03 ET

New Survey Results from 3,000 Postmenopausal Women Living with Vulvar and Vaginal Atrophy

 A new survey of more than 3,000 postmenopausal women reveals that women living with vulvar and vaginal atrophy (VVA) are either unaware of...

Feb 26, 2013, 15:10 ET

Shionogi Receives FDA Approval For Osphena™ (Ospemifene) For The Treatment Of Dyspareunia, A Symptom Of Vulvar And Vaginal Atrophy (VVA), Due To Menopause

 Shionogi Inc., the United States (U.S.)-based company of Shionogi & Co., Ltd., today announced that the U.S. Food and Drug Administration...

Jul 26, 2012, 16:30 ET

Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naive Adults with HIV-1

Shionogi-ViiV Healthcare LLC today announced 48-week data from the SPRING-2 Phase III study, which is evaluating the investigational integrase...

Jul 11, 2012, 02:08 ET

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV

Shionogi-ViiV Healthcare LLC today announced that initial results have been received from the Phase III SINGLE (ING114467) study of the...

Apr 02, 2012, 02:09 ET

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV

 ViiV Healthcare and Shionogi & Co., Ltd. today announced that initial results have been received from the SPRING-2 (ING113086) Phase III...

Jan 25, 2012, 08:00 ET

Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions

 Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced results from two studies published online today in...

Aug 04, 2011, 08:00 ET
HEAD LICE RETURNS TO SCHOOL: 5 TIPS TO AVOID PANIC.  (PRNewsFoto/Shionogi Inc.)

Head Lice Returns to School: Five Tips to Avoid Panic and Worry

It's back-to-school season and for many families, that means new morning routines, homework and head lice. To view the multimedia assets...

May 09, 2011, 08:00 ET
Apr 07, 2011, 08:00 ET

Shionogi Announces Commercial Availability of CUVPOSA™ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™...

Feb 03, 2011, 03:00 ET

Shionogi-ViiV Healthcare Starts Phase III Trial for '572-Trii' Fixed-Dose Combination HIV Therapy

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new...

Jan 10, 2011, 08:20 ET

Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced a true milestone as it marks the first commercial...

Oct 21, 2010, 04:00 ET

Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor

Shionogi-ViiV Healthcare LLC today announced the start of the Phase III clinical programme evaluating its once-daily, unboosted investigational...

Oct 04, 2010, 08:00 ET

Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD

Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of the...

Jul 29, 2010, 08:22 ET

Shionogi Inc. Announces FDA Approval of CUVPOSA™ for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions

Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of...

Jul 22, 2010, 08:30 ET

Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference

Shionogi-ViiV Healthcare LLC today reported data from two Phase IIb studies showing that its once-daily, unboosted investigational integrase...

Jul 21, 2010, 04:00 ET

Shionogi-ViiV Healthcare Announces Commitment to Phase III Development Program for Investigational Once-Daily HIV Integrase Inhibitor

Shionogi-ViiV Healthcare LLC today announced that it will be progressing its once-daily, unboosted investigational integrase inhibitor,...

Jun 01, 2010, 08:00 ET

Pivotal Data for the Investigational Treatment PSD502 for Primary Premature Ejaculation in the United States to be Presented at Major Medical Meeting

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer